Bioadaptives Stock Probability Of Bankruptcy
| BDPT Stock | USD 0.10 0.06 150.00% |
BioAdaptives |
BioAdaptives Company probability of financial unrest Analysis
BioAdaptives' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current BioAdaptives Probability Of Bankruptcy | Over 71% |
Most of BioAdaptives' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioAdaptives is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of BioAdaptives probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting BioAdaptives odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of BioAdaptives financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, BioAdaptives has a Probability Of Bankruptcy of 71%. This is 96.24% higher than that of the Consumer Defensive sector and 70.67% higher than that of the Packaged Foods industry. The probability of bankruptcy for all United States stocks is 78.26% lower than that of the firm.
BioAdaptives Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioAdaptives' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of BioAdaptives could also be used in its relative valuation, which is a method of valuing BioAdaptives by comparing valuation metrics of similar companies.BioAdaptives is rated second in probability of bankruptcy category among its peers.
BioAdaptives Fundamentals
| Return On Asset | -3.43 | |||
| Operating Margin | (33.58) % | |||
| Current Valuation | 544.74 K | |||
| Shares Outstanding | 160.49 M | |||
| Shares Owned By Insiders | 7.39 % | |||
| Price To Earning | (14.28) X | |||
| Price To Sales | 7.53 X | |||
| Revenue | 19.78 K | |||
| Gross Profit | 10.11 K | |||
| EBITDA | (643.76 K) | |||
| Net Income | (1.05 M) | |||
| Cash And Equivalents | 49.58 K | |||
| Total Debt | 450.26 K | |||
| Current Ratio | 0.04 X | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (158.65 K) | |||
| Earnings Per Share | (0.02) X | |||
| Beta | -0.29 | |||
| Market Capitalization | 144.44 K | |||
| Total Asset | 148.59 K | |||
| Retained Earnings | (2.96 M) | |||
| Working Capital | (160 K) | |||
| Current Asset | 156 K | |||
| Current Liabilities | 316 K | |||
| Z Score | -41.0 | |||
| Net Asset | 148.59 K |
About BioAdaptives Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioAdaptives's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioAdaptives using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioAdaptives based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for BioAdaptives Pink Sheet Analysis
When running BioAdaptives' price analysis, check to measure BioAdaptives' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAdaptives is operating at the current time. Most of BioAdaptives' value examination focuses on studying past and present price action to predict the probability of BioAdaptives' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAdaptives' price. Additionally, you may evaluate how the addition of BioAdaptives to your portfolios can decrease your overall portfolio volatility.